Trial Profile
A phase II study of neoadjuvant gemcitabine and oxaliplatin in patients with potentially resectable previously untreated pancreatic adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Jul 2014 Status changed from active, no longer recruiting to completed according to results published in the Annals of Surgery.
- 23 Sep 2013 Planned end date changed from 1 Oct 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 07 Sep 2012 Planned end date changed from 1 Oct 2010 to 1 Oct 2013 as reported by ClinicalTrials.gov.